detomidine

Detomidine is a nonnarcotic, synthetic α2-adrenergic agonist. Detomidine produces dose-dependent sedative and analgesic effects.

Detomidine hydrochloride (MPV-253 AII) produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors.

Detomidine carboxylic acid is the main urine metabolite of detomidine. Detomidine is a synthetic α2-adrenergic agonist and an animal analgesic. Detomidine also has heart and breathing effects, and has a diuretic effect.

Dexmedetomidine is a Central alpha-2 Adrenergic Agonist. The mechanism of action of dexmedetomidine is as an Adrenergic alpha2-Agonist. The physiologic effect of dexmedetomidine is by means of General Anesthesia.

Dexmedetomidine hydrochloride (Precedex) is a potent, selective, orally active α2-adrenoceptor agonist with a Ki value of 1.08 nM. It shows 1620-fold selectivity over α1-adrenoceptors. Dexmedetomidine hydrochloride (Precedex) can protect against sepsis-induced acute lung injury through anti-inflammatory, anti-oxidative, and anti-apoptotic effects.

Medetomidine hydrochloride (MPV785) is a selective α2-adrenoceptor agonist, with Ki of 1.08 nM, exhibts 1620-fold selectivity over α1-adrenoceptor.

Medetomidine (MPV785 free base) is a selective and orally available α2-adrenoceptor agonist, Ki=1.08 nM, with sedative and analgesic effects and vasoconstrictive hypoxic side effects, and is commonly used in small animal anesthesia.

3-Hydroxy Medetomidine, a metabolite of the α2-adrenergic receptor agonist Medetomidine, is actively involved in the biochemical pathways following the administration of Medetomidine.